Mikkel A. Algire

AbbVie (United States) US

Publications

8,040

Citations

H-Index

i10-Index

2yr Mean Cite

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome

Daniel G. Gibson, John I. Glass, Carole Lartigue, Vladimir N. Noskov, Ray-Yuan Chuang +19 more

Science 2010

2,631

Complete Chemical Synthesis, Assembly, and Cloning of a <i>Mycoplasma genitalium</i> Genome

Daniel G. Gibson, Gwynedd A. Benders, Cynthia Andrews‐Pfannkoch, Evgeniya A. Denisova, Holly Baden-Tillson +12 more

Science 2008

1,233

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours OA

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji, Wei Qiu, Debra Montgomery +34 more

Nature 2017

828

One-step assembly in yeast of 25 overlapping DNA fragments to form a complete synthetic <i>Mycoplasma genitalium</i> genome OA

Daniel G. Gibson, Gwynedd A. Benders, Kevin Axelrod, Jayshree Zaveri, Mikkel A. Algire +5 more

Proceedings of the National Academy of Sciences 2008

487

The Eukaryotic Translation Initiation Factors eIF1 and eIF1A Induce an Open Conformation of the 40S Ribosome OA

Lori A. Passmore, T.M. Schmeing, David Maag, Drew J. Applefield, Michael Acker +3 more

Molecular Cell 2007

332

Publications

47 total

Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis In Vivo.

J. Randolph, M. O'Connor, Feifei Han, C. Hutchins, Y. A. Siu - Journal of Medicinal Chemistry, 2023

Cited by 37 Semantic Scholar

Discovery of a Potent and Selective Covalent p300/CBP Inhibitor. OA

A. Mastracchio, C. Lai, E. DiGiammarino, Damien B. Ready, Loren M. Lasko - ACS Medicinal Chemistry Letters, 2021

Cited by 20 Semantic Scholar

Discovery of Spirohydantoins as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases. OA

Zhiqin Ji, R. Clark, Vikram Bhat, T. Matthew Hansen, Loren M. Lasko - Bioorganic & Medicinal Chemistry Letters, 2021

Cited by 16 Semantic Scholar

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

Todd A. Hopkins, William B. Ainsworth, Paul A. Ellis, Cherrie K. Donawho, Enrico L. DiGiammarino et al. - Molecular Cancer Research, 2018

Cited by 251 OpenAlex

Abstract LB-A23: Discovery of a potent catalytic p300/CBP inhibitor that targets lineage-specific tumors

K. Bromberg, Loren M. Lasko, C. Jakob, W. Qiu, D. Montgomery - Unknown Venue, 2018

Cited by 8 Semantic Scholar

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours OA

Loren M. Lasko, C. Jakob, Rohinton P. Edalji, W. Qiu, D. Montgomery - Nature, 2018

Cited by 9 Semantic Scholar

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours PDF

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji, Wei Qiu, Debra Montgomery et al. - Nature, 2017

Cited by 828 OpenAlex

The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex PDF

Yupeng He, Sujatha Selvaraju, Michael L. Curtin, Clarissa G. Jakob, Haizhong Zhu et al. - Nature Chemical Biology, 2017

Cited by 233 OpenAlex

The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity PDF

Kenneth D. Bromberg, Taylor R. H. Mitchell, Anup K. Upadhyay, Clarissa G. Jakob, Manisha Jhala et al. - Nature Chemical Biology, 2017

Cited by 128 OpenAlex

SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).

M. Curtin, H. Heyman, Richard F. Clark, Bryan K. Sorensen, George A. Doherty - Bioorganic & Medicinal Chemistry Letters, 2017

Cited by 18 Semantic Scholar

Research Topics

PARP inhibition in cancer therapy (15) RNA and protein synthesis mechanisms (9) Epigenetics and DNA Methylation (8) Bacteriophages and microbial interactions (8) RNA modifications and cancer (7)

Frequent Co-Authors

Daniel G. Gibson

6 joint publications

J. Craig Venter

6 joint publications

David Maag

6 joint publications

John I. Glass

5 joint publications

Gwynedd A. Benders

5 joint publications

Chuck Merryman

5 joint publications

Affiliations

Google (United States)

US 2012 - 2012

J. Craig Venter Institute

US 2013 - 2008

Johns Hopkins University

US 2010 - 2002

Johns Hopkins Medicine

US 2010 - 2002

AbbVie (United States)

US 2023 - 2015

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers

Mikkel A. Algire

Publication & Citation Trends

Most Cited Works

Publications

Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis In Vivo.

Discovery of a Potent and Selective Covalent p300/CBP Inhibitor. OA

Discovery of Spirohydantoins as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases. OA

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow

Abstract LB-A23: Discovery of a potent catalytic p300/CBP inhibitor that targets lineage-specific tumors

Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours OA

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours PDF

The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex PDF

The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity PDF

SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).

Research Topics

Frequent Co-Authors

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back